» Articles » PMID: 37908266

MEN1 in a Patient With Nonsyndromic Familial Nonmedullary Thyroid Carcinoma

Overview
Journal JCEM Case Rep
Specialty Endocrinology
Date 2023 Nov 1
PMID 37908266
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical syndromes involving multiple endocrine glands have been well recognized for over a century. Multiple reports describing hereditary multiple endocrine neoplasia (MEN) syndromes involving pituitary, parathyroid, and pancreatic neuroendocrine tumors have been published. Differentiated (nonmedullary) thyroid cancer can also present as a hereditary syndrome with or without a specific genetic predisposition. We report the case of a man with nonsyndromic familial nonmedullary thyroid carcinoma, a pituitary adenoma, hyperparathyroidism, an adrenal adenoma, and pancreatic adenocarcinoma. Genetic testing did not reveal mutations in the commonly reported genes associated with MEN syndromes. MEN1 is characterized by endocrine neoplasia in at least 2 of the following glands: pituitary, parathyroid, and the gastro-entero-pancreatic (GEP) tract. Co-occurrence of MEN1 with familial nonmedullary thyroid carcinoma, however, has not been reported in the medical literature. This unique case of MEN1 co-existing in a patient with nonsyndromic familial thyroid carcinoma was not associated with any common MEN syndrome germline mutations.

Citing Articles

Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, Gene-Related Tumors, and Insulin Resistance.

Carsote M, Nistor C, Gheorghe A, Sima O, Trandafir A, Nistor T Int J Mol Sci. 2024; 25(12).

PMID: 38928056 PMC: 11203827. DOI: 10.3390/ijms25126349.

References
1.
Lincoln S, Truty R, Lin C, Zook J, Paul J, Ramey V . A Rigorous Interlaboratory Examination of the Need to Confirm Next-Generation Sequencing-Detected Variants with an Orthogonal Method in Clinical Genetic Testing. J Mol Diagn. 2019; 21(2):318-329. PMC: 6629256. DOI: 10.1016/j.jmoldx.2018.10.009. View

2.
Capezzone M, Robenshtok E, Cantara S, Castagna M . Familial non-medullary thyroid cancer: a critical review. J Endocrinol Invest. 2020; 44(5):943-950. PMC: 8049908. DOI: 10.1007/s40618-020-01435-x. View

3.
McDonnell J, Gild M, Clifton-Bligh R, Robinson B . Multiple endocrine neoplasia: an update. Intern Med J. 2019; 49(8):954-961. DOI: 10.1111/imj.14394. View

4.
Sanchez-Ares M, Cameselle-Garcia S, Abdulkader-Nallib I, Rodriguez-Carnero G, Beiras-Sarasquete C, Punal-Rodriguez J . Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys. Front Endocrinol (Lausanne). 2022; 13:829103. PMC: 8918666. DOI: 10.3389/fendo.2022.829103. View

5.
de Carlos Artajo J, Irigaray Echarri A, Garcia Torres J, Pineda Arribas J, Lorea A, Eguilaz Esparza N . Clinical characteristics and prognosis of familial nonmedullary thyroid carcinoma. Endocrinol Diabetes Nutr (Engl Ed). 2022; 69(4):262-270. DOI: 10.1016/j.endien.2022.03.003. View